Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01254136 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer
A Phase 1 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01254136 is a Phase 1 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 20 participants.
The verdict
NCT01254136, a Phase 1 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This Phase I/II study is designed to assess the safety and therapeutic effect of INCB007839 in combination with trastuzumab and vinorelbine in patients with metastatic HER2+ breast cancer.
Interventions
- DRUG Trastuzumab
- DRUG Vinorelbine
- DRUG INCB007839 300mg BID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-10 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01254136
The ClinicalTrials.gov registry entry for NCT01254136 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Trastuzumab is the first listed.
NCT01254136 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01254136 about?
NCT01254136 is a clinical study titled "Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer". This Phase I/II study is designed to assess the safety and therapeutic effect of INCB007839 in combination with trastuzumab and vinorelbine in patients with metastatic HER2+ breast cancer.
What is the current status of trial NCT01254136?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2010-10. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01254136?
The interventions under investigation include: Trastuzumab (DRUG), Vinorelbine (DRUG), INCB007839 300mg BID (DRUG).
Who is sponsoring clinical trial NCT01254136?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.